Journal of Biomolecular Screening

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dhar, S.
Right arrow Articles by Larsson, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Dhar, S.
Right arrow Articles by Larsson, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Biomolecular Screening, Vol. 3, No. 3, 207-216 (1998)
DOI: 10.1177/108705719800300307

A Nonclonogenic Cytotoxicity Assay Using Primary Cultures of Patient Tumor Cells for Anticancer Drug Screening

Sumeer Dhar

Division of Clinical Pharmacology, University Hospital, Uppsala University, Uppsala, Sweden

Joachim Gullbo

Division of Clinical Pharmacology, University Hospital, Uppsala University, Uppsala, Sweden

Kenneth Nilsson

Department of Pathology, University Hospital, Uppsala University, Uppsala, Sweden

Peter Nygren

Department of Oncology, University Hospital, Uppsala University, Uppsala, Sweden

Rolf Larsson

Division of Clinical Pharmacology, University Hospital, Uppsala University, Uppsala, Sweden

Primary cultures of cells from patients with chronic lymphocytic leukemia (CLL) and ovarian carcinoma (Ovca) were compared with the renal carcinoma ACHN and the lymphocytic CCRF-CEM human tumor cell lines in response to 63 toxic or nontoxic compounds. The experiments were conducted at 1, 10, and 100 µ/ml in 96-well microtiter plates for an assay time of 72 h. The plates were analyzed by the fully automated Dynatech Immuno Assay System (DIAS) using Alamar blue as a fluorometric/colorimetric indicator of metabolic activity. Drug response data were reported as the area under the tumor cell survival-concentration curve (AUC). Noncytotoxic compounds were classified as inactive by all cell systems. According to the AUC, CCRF-CEM and CLL cells were the most sensitive, followed by ACHN, and then Ovca. Many of the clinically active drugs were detected by all cell systems. However, the sensitivity pattern differed considerably between the cell types as judged from correlation analysis, and a higher proportion of clinically inactive drugs were scored as active by the cell lines compared with the primary cultures. Ovca showed the highest ratio of clinically solid tumor active/clinically inactive agents followed by CLL. The results indicate that primary cultures of human tumor cells may be a useful and valuable model for anticancer drug screening.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J Biomol ScreenHome page
P. Lindholm, J. Gullbo, P. Claeson, U. Goransson, S. Johansson, A. Backlund, R. Larsson, and L. Bohlin
Selective Cytotoxicity Evaluation in Anticancer Drug Screening of Fractionated Plant Extracts
J Biomol Screen, August 1, 2002; 7(4): 333 - 340.
[Abstract] [PDF]